When is Neuphoria Therapeutics next earning report and what to expect from it

Impact of AFFIRM-1 Phase 3 Topline Readout on Neuphoria Therapeutics (NEUP)

The upcoming topline results from Neuphoria Therapeutics' (NEUP) AFFIRM-1 Phase 3 clinical trial for BNC-210 in social anxiety disorder represent a critical near-term catalyst for the company. As of May 20, 2025, the company stated these results were "on track" for Q3 2025, making their release imminent or very recent. The outcome of this trial is expected to significantly influence NEUP's stock performance and future analyst ratings.

Potential Stock Performance Impact

• Positive Results: A successful readout, demonstrating statistically significant and clinically meaningful efficacy for BNC-210, would likely lead to a substantial positive re-rating of NEUP's stock. Given the current share price of $7.87 as of August 6, 2025, and an average one-year analyst price target of $21.42, positive news could see the stock surge towards or even exceed this target. Such an outcome would validate the therapeutic potential of BNC-210 and significantly de-risk the company's development pathway.
• Negative or Mixed Results: Conversely, an unfavorable or inconclusive outcome would likely result in a sharp decline in stock value. Biotech companies are highly sensitive to clinical trial results, and a failure at Phase 3 can severely impact investor confidence, potentially jeopardizing future funding and development plans. This would put pressure on the company's stated cash runway, which extends into Q3 2026.

Analyst Ratings and Price Targets

Analyst ratings and price targets are highly reactive to clinical trial data.

• Upgrades and Increased Targets: Positive AFFIRM-1 results would almost certainly trigger upgrades from existing analysts, such as HC Wainwright & Co., which currently maintains a "Buy" rating on NEUP. New analysts might also initiate coverage, and price targets would likely be revised upwards to reflect the increased probability of market approval and commercialization.
• Downgrades and Reduced Targets: In the event of negative results, analysts would likely downgrade their recommendations, reduce price targets, and potentially withdraw coverage, reflecting a diminished outlook for BNC-210 and the company's prospects.

Investors should closely monitor official company announcements and SEC filings for the definitive trial results and subsequent market and analyst reactions. Fintel's NEUP page provides comprehensive data on analyst ratings, price targets, and institutional ownership changes, which will be crucial for understanding the post-readout landscape.